Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ChemoMetec

521.50 DKK-0.67 %25.9, 10.34
Less than 1K followers

CHEMM

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.67 %
+7.08 %
+42.33 %
+120.23 %
-24.15 %
-18.32 %
+54.84 %
-52.24 %
+2,270.45 %

ChemoMetec specializes in the design, development, and production of patented instruments for cell counting and cell analysis. The company cooperates and statutes agreements with actors such as research institutes, universities, food companies, hospitals, and specialist clinics. Customers are found in a global market. The company was founded in 1997 and is headquartered in Alleröd, Denmark.

Read more
Market cap
9.08B DKK
Turnover
2.68M DKK
Revenue
511.06M
EBIT %
49.11 %
P/E
44.96
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.10
2026

General meeting '26

3.2
2027

Interim report Q2'27

9.9
2027

Annual report '27

Regulatory press release16.09.2026, 14.37

Major shareholder announcement - BlackRock, Inc.

ChemoMetec
Regulatory press release16.09.2026, 14.37

Storaktionærmeddelelse - BlackRock, Inc.

ChemoMetec
Regulatory press release16.09.2026, 14.22

Indkaldelse til ordinær generalforsamling 2026

ChemoMetec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release16.09.2026, 14.22

Notice of Annual General Meeting 2026

ChemoMetec
HCA Morgenbørs 11/09 - Movinn CEO-Interview og fokus på eftermiddagens inflationstal
Video11.09.2026, 09.20 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 11/09 - Movinn CEO-Interview og fokus på eftermiddagens inflationstal

Europæiske futures indikerer en positiv åbning på en dag, hvor fokus er rettet mod eftermiddagens amerikanske inflationstal. Herhjemme vil der blandt andet være fokus på ChemoMetec, Novonesis, ISS, Ørsted og Novo Nordisk. Gæst i studiet her til morgen er CEO, Patrick Block fra Movinn.

ØrstedChemoMetecISSNovo NordiskNovonesisA.P. Møller - Mærsk
Regulatory press release10.09.2026, 20.39

Positionering til fremtidig vækst

ChemoMetec
Regulatory press release10.09.2026, 20.39

Positioning ChemoMetec for future growth

ChemoMetec
Regulatory press release10.09.2026, 20.20

Forventninger til regnskabsåret 2026/27

ChemoMetec
Regulatory press release10.09.2026, 20.20

Guidance for the 2026/27 financial year

ChemoMetec
HCA Morgenbørs 07/09 - ChemoMetec i fokus i interview med Tobias Friis og udsigt til faldende markeder
Video07.09.2026, 09.21 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 07/09 - ChemoMetec i fokus i interview med Tobias Friis og udsigt til faldende markeder

Udsigt til let faldende markeder fra morgenstunden i Europa trods stigende markeder i det meste af Asien. Gæst i studiet her til morgen er porteføljeforvalter Tobias Friis fra Fundamental Fondsmæglerselskab.

ChemoMetecSkjern BankA.P. Møller - MærskØrstedHafniaSJF BankMøns Bank
HCA Morgenbørs 03/09 - Jakob Have interview og stilstand i oliepris og renter
Video03.09.2026, 11.09 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 03/09 - Jakob Have interview og stilstand i oliepris og renter

Markederne kæmper med at finde retning trods stilstand i oliepris og renter. Herhjemme fokus på analytikerændringer og nyheder. Gæst i studiet her til morgen er Jakob Have fra Nordic Compound Invest.

Donkey RepublicNetcompany GroupChemoMetecGomSpacePandoraLundbeckNNITSkjern Bank
HCA Morgenbørs 24/08 - WindowMaster CEO-interview og negativ åbning i Europa
Video24.08.2026, 09.31 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 24/08 - WindowMaster CEO-interview og negativ åbning i Europa

Udsigt til negativ åbning i Europa efter kursfald i Asien her til morgen. Ingen større danske regnskaber i dag, men en lang række kursmålsændringer fra analytikerkorpset. Gæst i studiet her til morgen er CEO Erik Boyter fra WindowMaster.

Novo NordiskNovonesisChemoMeteccBrainBavarian NordicGubraWindowMaster International
Regulatory press release10.08.2026, 12.32

ChemoMetec enters collaboration agreement with Roche Diagnostics

ChemoMetec
Press release07.08.2026, 15.04

ChemoMetec A/S invites to conference call on September 11, 2026 at 3:00 p.m. CEST on its upcoming 2025/26 Annual Report

ChemoMetec
Press release07.08.2026, 15.04

ChemoMetec A/S afholder telefonkonference den 11. september 2026 kl. 15.00 til præsentation af den kommende årsrapport for 2025/26

ChemoMetec
Regulatory press release01.08.2026, 10.24

Appointment of new CFO

ChemoMetec
Regulatory press release01.08.2026, 10.24

Udnævnelse af ny CFO

ChemoMetec
HCA Morgenbørs 26/05 - Lukkede markeder ser ud til at skulle catche op på mandagens stigninger
Video26.05.2026, 09.13 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 26/05 - Lukkede markeder ser ud til at skulle catche op på mandagens stigninger

I dagens Morgenbørs ser vi ind i blandede futures fra morgenstunden. Herhjemme, lukkede markeder ser ud til at skulle catche op på mandagens stigninger.

ChemoMetecRockwoolGrønlandsbankenTCM GroupLundbeckNovo Nordisk
HCA Morgenbørs 18/05 - Negative futures og lange renter stiger
Video18.05.2026, 09.18 by
Michael Friis, Victor Skriver

HCA Morgenbørs 18/05 - Negative futures og lange renter stiger

I dagens Morgenbørs ser vi ind i negative futures, lange renter stiger. Herhjemme er der fokus på Novo, NKT, RTX og Chemometec.

NKTChemoMetecA.P. Møller - MærskRTXNovo NordiskGN Store NordColoplastTorm
Regulatory press release15.05.2026, 11.43

Initiation of buy-back programme

ChemoMetec